文献速递细菌感染、耐药与抗菌药物医院感染防控

在亟需关注抗菌药物耐药性的艰难梭菌中,体内出现对非达霉素仍不常见的耐药

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

一例38岁男性医院获得性艰难梭菌感染患者,首次发作接受非达霉素治疗后复发,复发分离株对非达霉素耐药(MIC 16 mg/L),全基因组测序提示rpoB基因T3428G突变可能相关,耐药伴随生长、产孢和产毒缺陷;文献仅检索到3株既往非达霉素耐药临床株。

要点

  • 单疗程非达霉素治疗后体内可快速出现耐药,复发株MIC为16 mg/L。
  • rpoB基因T3428G突变可能与非达霉素耐药相关。
  • 耐药伴随生长、产孢和产毒缺陷,临床意义尚待阐明。

核心结论

  • 非达霉素耐药虽罕见,但单疗程治疗后可在体内快速出现。
  • 该观察支持对艰难梭菌治疗药物敏感性进行前瞻性监测。
  • 非达霉素耐药的临床相关性仍需阐明,尤其因其表观罕见并伴随适合度代价。

研究设计与样本

  • 病例报告:一例38岁男性医院获得性艰难梭菌感染患者,首次发作接受非达霉素治疗。
  • 对连续分离株进行表型表征(抗菌药物敏感性、生长、产孢能力和产毒)及全基因组测序分析。
  • 同时进行文献综述。

主要发现

  • 复发分离株出现非达霉素耐药,MIC为16 mg/L。
  • 全基因组测序显示菌株间遗传关系密切,提示该患者为复发。
  • rpoB基因T3428G突变可能与非达霉素耐药相关。
  • 耐药与生长、产孢和产毒缺陷相关。
  • 文献综述仅发现3株既往非达霉素耐药艰难梭菌临床株。

局限性

  • 非达霉素耐药的临床相关性仍需阐明,尤其因其表观罕见并伴随适合度代价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fidaxomicin is a first-line treatment for Clostridioides difficile infections (CDIs). Fidaxomicin resistance has rarely been reported in this urgent antimicrobial resistance threat as defined by the CDC. OBJECTIVES: To report a case of fidaxomicin-resistant C. difficile isolation in a patient treated by fidaxomicin, characterize the genetic determinant for resistance and the consequences on pathophysiological traits, and review the literature. PATIENT AND METHODS: A 38-year-old male patient with several risk factors for CDI experienced three episodes of hospital-acquired CDI and received fidaxomicin for the first episode. The successive isolates were subjected to phenotypic characterization (antimicrobial susceptibility, growth, sporulation ability and toxin production) and WGS analysis to evaluate clonality and modifications associated with resistance. RESULTS: Resistance to fidaxomicin arose in isolates from the recurrences of CDI (MIC: 16 mg/L). WGS analysis showed a close genetic link between strains suggestive of relapses in this patient. A T3428G mutation in the rpoB gene might be associated with fidaxomicin resistance. The resistance was associated with defects in growth, sporulation and production of toxins. A review of the literature found only three previous fidaxomicin-resistant C. difficile clinical strains. CONCLUSIONS: Although rarely reported, resistance to fidaxomicin may quickly emerge in vivo after a single course of treatment. This observation supports the need for prospective surveillance of the susceptibility of C. difficile to treatment antibiotics. However, the clinical relevance of fidaxomicin resistance still needs to be elucidated, particularly due to its apparent rareness and associated fitness cost.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Marchandin H, Anjou C, Poulen G, et al. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. J Antimicrob Chemother. 2023. PMID: 37352110. doi:10.1093/jac/dkad194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。